These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7353373)

  • 21. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
    Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
    Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 24. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)].
    Bulla M; Delling G; Benz-Bohm G; Stock GJ; Sánchez de Reutter A; Ziegler R; Lühmann H; Severin M; Kalbitzer E; Manegold C
    Klin Wochenschr; 1980 May; 58(10):511-9. PubMed ID: 7392529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal osteodystrophy: the importance of 1-alpha-OH-D3].
    Berland Y; Olmer M; Grandvuillemin M; Lachaize AM
    Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy.
    Brickman AS; Coburn JW; Sherrard DJ; Wong EG; Norman AW; Singer FR
    Contrib Nephrol; 1980; 18():29-41. PubMed ID: 7353378
    [No Abstract]   [Full Text] [Related]  

  • 28. 1,25-Dihydroxycholecalciferol in dialysed patients with clinically asymptomatic renal osteodystrophy. A controlled study.
    Fischer JA; Binswanger U
    Contrib Nephrol; 1980; 18():82-91. PubMed ID: 7353381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal hypophosphatemic rickets: growth acceleration after long-term treatment with 1,25-dihydroxyvitamin-D3.
    Chan JC; Lovinger RD; Mamunes P
    Pediatrics; 1980 Sep; 66(3):445-54. PubMed ID: 6893489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
    Moorthy AV; Harrington AR; Mazess RB; Simpson DP
    Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term experience of alfacalcidol in renal osteodystrophy.
    Sharman VL; Brownjohn AM; Goodwin FJ; Hately W; Manning RM; O'Riordan JH; Papapoulos SE; Marsh FP
    Q J Med; 1982; 51(203):271-8. PubMed ID: 7146311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 24,25 dihydroxycalciferol: assay in non-anephric patients on chronic haemodialysis and assessment of its possible pathophysiological role in renal osteodystrophy.
    Lambrey G; Nguyen TM; Fournier A; Sebert JL; Kassouf J; de Fremont JF; Marie P; Meunier P; Caillens C; Gueris J; Garabedian M; Balsan S
    Proc Eur Dial Transplant Assoc; 1980; 17():548-56. PubMed ID: 6972530
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H; Bordier P
    Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
    [No Abstract]   [Full Text] [Related]  

  • 34. The effect of 1,25 (OH)2D3 on bone mineralization: ultrastructural studies in patients with renal osteodystrophy.
    Krempien B; Ritz E; Tschöpe W
    Contrib Nephrol; 1980; 18():122-34. PubMed ID: 7353371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 36. 1,25-Dihydroxyvitamin D3 in childhood hepatic osteodystrophy.
    Heubi JE; Tsang RC; Steichen JJ; Chan GM; Chen IW; DeLuca HF
    J Pediatr; 1979 Jun; 94(6):977-82. PubMed ID: 448553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The kidney as an endocrine organ involved in the function of vitamin D.
    DeLuca HF
    Am J Med; 1975 Jan; 58(1):39-47. PubMed ID: 163578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy.
    Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW
    Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3.
    Pierides AM; Skillen AW; Ellis HA
    J Lab Clin Med; 1979 Jun; 93(6):899-909. PubMed ID: 438610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
    Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.